Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caretha L Creasy

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Nature Medicine|April 8, 2017
Untangling the role of mutant histone H3 in diffuse intrinsic pontine gliomaCaretha L Creasy
Epigenomics|August 12, 2014
EZH2 as a potential target in cancer therapyMichael T McCabe, Caretha L Creasy
Nature Medicine|March 8, 2019
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancerHelai P Mohammad, Olena Barbash, Caretha L Creasy
The Journal of Biological Chemistry|February 7, 2013
The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 proteinSonali Jalan Rawat, Caretha L Creasy, Jeffrey R Peterson, et al.
Current Genetics|April 2, 2004
The yeast Pho80-Pho85 cyclin-CDK complex has multiple substratesNorman C Waters, Janine P Knight, Caretha L Creasy, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 7, 2011
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesHua Li, Benjamin G Bitler, Vinod Vathipadiekal, et al.
Oncotarget|December 3, 2013
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerAnastasia Wyce, Yan Degenhardt, Yuchen Bai, et al.
The Journal of Biological Chemistry|October 17, 2001
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motifL Miguel Martins, Ingram Iaccarino, Tencho Tenev, et al.
Cancer Science|November 10, 2017
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabineMasafumi Ikeda, Tatsuya Ioka, Akira Fukutomi, et al.
Scientific Reports|December 18, 2020
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissuesPaul B Noto, Timothy W Sikorski, Francesca Zappacosta, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Nature Medicine|April 8, 2017
Untangling the role of mutant histone H3 in diffuse intrinsic pontine gliomaCaretha L Creasy
Epigenomics|August 12, 2014
EZH2 as a potential target in cancer therapyMichael T McCabe, Caretha L Creasy
Nature Medicine|March 8, 2019
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancerHelai P Mohammad, Olena Barbash, Caretha L Creasy
The Journal of Biological Chemistry|February 7, 2013
The tumor suppressor Mst1 promotes changes in the cellular redox state by phosphorylation and inactivation of peroxiredoxin-1 proteinSonali Jalan Rawat, Caretha L Creasy, Jeffrey R Peterson, et al.
Current Genetics|April 2, 2004
The yeast Pho80-Pho85 cyclin-CDK complex has multiple substratesNorman C Waters, Janine P Knight, Caretha L Creasy, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 7, 2011
ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesHua Li, Benjamin G Bitler, Vinod Vathipadiekal, et al.
Oncotarget|December 3, 2013
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancerAnastasia Wyce, Yan Degenhardt, Yuchen Bai, et al.
The Journal of Biological Chemistry|October 17, 2001
The serine protease Omi/HtrA2 regulates apoptosis by binding XIAP through a reaper-like motifL Miguel Martins, Ingram Iaccarino, Tencho Tenev, et al.
Cancer Science|November 10, 2017
Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabineMasafumi Ikeda, Tatsuya Ioka, Akira Fukutomi, et al.
Scientific Reports|December 18, 2020
Identification of hnRNP-A1 as a pharmacodynamic biomarker of type I PRMT inhibition in blood and tumor tissuesPaul B Noto, Timothy W Sikorski, Francesca Zappacosta, et al.
Pageof 3